Drugs / FluMist® Quadrivalent

Trials 3 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03898986 Oct 2019 → Dec 2023 influenza Stanford University Completed No outcome recorded
Phase 1 NCT03088904 Oct 2014 → Dec 2018 influenza Stanford University Completed No outcome recorded
Phase 1 NCT02950688 ? → Dec 2020 influenza National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02474901 Comparator Jul 2013 → Mar 2016 HIV infectious disease University of Colorado, Denver Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2023-10-24 AstraZeneca US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FluMist Quadrivalent astrazeneca.com

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as FluMist Quadrivalent ClinicalTrials.gov intervention name — accepted as the source's own label NCT03088904
Known as Live attenuated influenza vaccine (LAIV4) ClinicalTrials.gov intervention name — accepted as the source's own label NCT03898986
Known as Quadrivalent Live Attenuated Influenza Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02474901
Known as Seasonal LAIV ClinicalTrials.gov intervention name — accepted as the source's own label NCT02950688
Modality Vaccine “QLAIV is an intranasal vaccineNCT02474901
Route Intranasal “QLAIV is an intranasal vaccine” NCT02474901